PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
-730.14
Negative P/E while Drug Manufacturers - Specialty & Generic median is 5.20. Seth Klarman would scrutinize path to profitability versus peers.
3047.52
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 9.50. Jim Chanos would check for potential multiple compression risks.
114.23
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.42. Jim Chanos would check for potential asset write-down risks.
-1007.98
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is 0.00. Seth Klarman would investigate cash flow improvement potential.
-1576.30
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is 0.00. Seth Klarman would investigate operational improvement potential.
114.23
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.46. Jim Chanos would check for valuation bubble risks.
-0.03%
Negative earnings while Drug Manufacturers - Specialty & Generic median yield is 0.12%. Seth Klarman would investigate path to profitability.
-0.10%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is 0.00%. Seth Klarman would investigate cash flow improvement potential.